ChemotherapyFDA-approvedFirst-line
Idarubicin
How it works
Interferes with DNA synthesis, preventing cancer cell growth and division.
Cancer types
Leukemia— All patients
Efficacy
Studies have shown that idarubicin can induce complete remission in around 30% of patients, with a median overall survival of approximately 9 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Researchers Identify New Potential Treatments for Lung Cancer | Lung Cancer | lab-study | The predicted IC values for idarubicin and larotrectinib were 226.55 nM and 479.06 nM, respectively. | Source → |
| Combining two drugs may help treat a type of leukemia | Leukemia | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.